Efficacy and Safety of NT 201 in the Treatment of Lateral Periorbital Wrinkles
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and safety of incobotulinumtoxinA (Xeomin) in comparison to
placebo in the treatment of moderate to severe lateral periorbital wrinkles at maximum smile
and to compare two different application schemes of Xeomin. Each subject will be treated on
the right and left eye area, using the same dose but different application schemes (i.e. 3 or
4 injection sites).
Phase:
Phase 3
Details
Lead Sponsor:
Merz Pharmaceuticals GmbH
Treatments:
abobotulinumtoxinA Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA